HSC(F)05-2014 (PDF 201 KB)

Update to Procurement Guidance Note 03/11 - Award of Contracts without a Competition

Closure of Space for health - PEL(13)05 (PDF 38KB)

This Professional Estates Letter informs HSC bodies of the closure of the Space for Health information service and the availability of DHSPPS estates and facilities management policy on the DHSSPS website.

Annual Report to the Equality Commission 04-05 (PDF 187 KB)

The Department’s Evaluation and Equality Unit provides advice and guidance to colleagues throughout the Department who are planning and undertaking reviews and evaluations of programmes, services and policies, and provides guidance and information to support the policy-making processes. In carrying out this function the Unit has continued to help colleagues to mainstream equality considerations into decision-making, reviews and evaluations from the earliest stages of these processes. åÊ

Nursing & Midwifery Workforce Planning - Final Report Sept 05 (PDF 239 KB)

Nursing & Midwifery Workforce Planning - Final Report Sept 05

Priorities For Action 2004/05 (PDF 427 KB)

PRIORITIES FOR ACTION- 2004/2005 Planning Priorities and Actions for the Health and Personal Social Services

Health Inequalities Target Data Web Tool - Updated to 2003-05

This tool contains the data for the LHO briefing "The London Health Inequalities Forecast: A briefing on inequalities in life expectancy and deaths from cancers, heart disease and stroke in London". The tool enables local areas to monitor their progress towards the national health inequalities targets for life expectancy, mortality from heart disease and stroke, and mortality from cancers.

Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.

Tamoxifen (tam) is a widely used endocrine therapy in the treatment of early and advanced stage breast cancer in women and men. It is a pro-drug having weak affinity with the estrogen receptor and needs to be converted to its main metabolite, endoxifen (endox), to have full anticancer activity. Cytochrome 2D6 (CYP2D6) plays a major role in the metabolism of tamoxifen to endoxifen. It is genetically highly polymorphic and its activity influences profoundly the synthesis of endoxifen and potentially the efficacy of tamoxifen treatment. Genotyping is currently the most widely used approach in studies and also in clinical practice to categorize patients as poor- (PM), intermediate- (IM), extensive- (EM) and ultra rapid-metabolizers (UM). Some clinicians already use genotyping in order to tailor the endocrine therapy of their patients. Owing to the large inter-individual variations in concentrations of the active moitey due to genetic and non-genetic influences renders the predictive value of the test uncertain for an individual patient. A significant number of patients classified as EM or IM by genotyping have indeed relatively low endoxifen levels similar to PMs1. This suggests that genotyping is probably not the opti ma l meth o d f or predi cti ng end oxif en l evels.

Prevalence and Clinical Characteristics of HIV Type 1-Infected Patients Receiving Dialysis in Spain: Results of a Spanish Survey in 2006: GESIDA 48/05 Study

End-stage renal diseases (ESRD) are becoming more frequent in HIV-infected patients. In Europe there is little information about HIV-infected patients on dialysis. A cross-sectional multicenter survey in 328 Spanish dialysis units was conducted in 2006. Information from 14,876 patients in dialysis was obtained (81.6% of the Spanish dialysis population). Eighty-one were HIV infected (0.54%; 95% CI, 0.43-0.67), 60 were on hemodialysis, and 21 were on peritoneal dialysis. The mean (range) age was 45 (28-73) years. Seventy-two percent were men and 33% were former drug users. The mean (range) time of HIV infection was 11 (1-27) years and time on dialysis was 4.6 (0.4-25) years. ESRD was due to glomerulonephritis (36%) and diabetes (15%). HIV-associated nephropathy was not reported. Eighty-five percent were on HAART, 76.5% had a CD4 T cell count above 200 cells, and 73% had undetectable viral load. Thirty-nine percent of patients met criteria for inclusion on the renal transplant (RT) waiting list but only 12% were included. Sixty-one percent had HCV coinfection. HCV-coinfected patients had a longer history of HIV, more previous AIDS events, parenteral transmission as the most common risk factor for acquiring HIV infection, and less access to the RT waiting list (p < 0.05). The prevalence of HIV infection in Spanish dialysis units in 2006 was 0.54% HCV coinfection was very frequent (61%) and the percentage of patients included on the Spanish RT waiting list was low (12%).

Notice d'estampes anciennes et modernes, portraits... / [expert] Vignères

[Vente. Estampes. 1859-05-23 - 1859-05-24. Paris]

Notice d'une collection d'estampes, portraits et sujets sur l'histoire de France... dessins de madame Meyer... / [expert] Vignères

[Vente. Estampes. 1857-03-05. Paris]